Multiple primary malignancies in patients with sporadic pancreatic endocrine tumors

Fendrich, Volker; Waldmann, Jens; Bartsch, Detlef K.; Schlosser, Katja; Rothmund, M.; Gerdes, Berthold

doi:10.1002/jso.21044

Cited by 11 publications

(7 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Non-endocrine neoplasms had been previously diagnosed in 70.0%% of the patients. Little information is available in the literature regarding the true incidence of second neoplasms in patients with NET (13)(14)(15). The association rate was 11.0% in our series, primarily with NET of the small bowel and pancreas (data not shown).…”

Section: Patient Populationmentioning

confidence: 59%

Observational study of patients with gastroenteropancreatic and bronchial neuroendocrine tumors in Argentina: Results from the large database of a multidisciplinary group clinical multicenter study

O’Connor

Marmissolle

Bestani³

et al. 2014

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. Neuroendocrine tumors (NET) include a spectrum of malignancies arising from neuroendocrine cells throughout the body. The objective of this clinical investigation of retrospectively and prospectively collected data was to describe the prevalence, demographic data, clinical symptoms and methods of diagnosis of NET and the treatment and long-term follow-up of patients with NET. Data were provided by the participating centers and assessed for consistency by internal reviewers. All the cases were centrally evaluated (when necessary) by the pathologists in our group. The tissue samples were reviewed by hematoxylin and eosin and immunohistochemical staining techniques to confirm the diagnosis of NET. In total, 532 cases were documented: 461 gastroenteropancreatic-NET (GEP-NET) and 71 bronchial NET (BNET). All the tumors were immunohistochemically defined according to the World Health Organization (WHO) and European Neuroendocrine Tumor Society criteria. The most common initial symptoms in GEP-NET were abdominal pain, diarrhea, bowel obstruction, flushing, gastrointestinal bleeding and weight loss. The most common tumor types were carcinoid (58.0%), non-functional pancreatic tumor (23.0%), metastatic NET of unknown primary (16.0%) and functional pancreatic tumor (3.0%). Of the BNET, 89.0% were typical and 11.0% atypical carcinoids. Of the patients with GEP-NET, 59.2% had distant metastasis at diagnosis. The locations of the primary tumors in GEP-NET were the small bowel (26.9%), pancreas (25.2%), colon-rectum (12.4%), appendix (7.6%), stomach (6.9%), esophagus (2.8%), duodenum (2.0%) and unknown primary (16.3%). The histological subtypes based on the WHO classification were well-differentiated NET (20.1%), well-differentiated neuroendocrine carcinomas (66.5%) and poorly differentiated neuroendocrine carcinomas (10.3%). Overall, 67.3% of the patients underwent surgery, 41.2% with curative intent and 26.1% for palliative purposes. The 5-year survival rates were 65.1% (95% confidence interval, 58.0-71.4%) in GEP-NET and 100.0% in typical carcinoid of the lung. This observational, non-interventional, longitudinal study aimed to accumulate relevant information regarding the epidemiology, clinical presentation and current practices in the treatment of NET patients in Argentina, providing insight into regional differences and patterns of care in this heterogeneous disease.

show abstract

Section: Patient Populationmentioning

confidence: 59%

Observational study of patients with gastroenteropancreatic and bronchial neuroendocrine tumors in Argentina: Results from the large database of a multidisciplinary group clinical multicenter study

O’Connor

Marmissolle

Bestani³

et al. 2014

Molecular and Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…Specifically, malignant gastrinomas and malignant NF-PNETs are associated with a wide range of other tumors, for example, ovarian, breast, endometrial, bladder, prostate, or esophageal cancer [24].…”

Section: Incidencementioning

confidence: 99%

Neuroendocrine Tumors of the Pancreas

et al. 2009

View full text Add to dashboard Cite

show abstract

“…It may be the result of accumulated growth stimulation by the secreted hormones or a genetic alteration that leads to tumorigenesis. [6] But the pathophysiology correlating with NET and adenocarcinoma is still unclear, and further studies are needed.…”

Section: Discussionmentioning

confidence: 99%

Double primary tumors of the pancreas

2018

View full text Add to dashboard Cite

Rationale:Adenocarcinoma and neuroendocrine tumors are a very rare combination of double primary pancreas tumor.Patient concerns:A Whipple operation was initially performed on a 64-year-old man to remove an adenocarcinoma. Four years after the operation, surveillance- computed tomography revealed abnormal findings of the pancreas. Recurrent adenocarcinoma and neuroendocrine tumor involving different sites of the remnant pancreas were simultaneously detected and characterized on computed tomography and magnetic resonance imaging.Diagnoses:The patient was diagnosed with recurrent adenocarcinoma and neuroendocrine tumor in the post-operative pancreas.Interventions:Radical pancreatosplenectomy was performed. The patient underwent subsequent chemotherapy and radiotherapy.Outcomes:No tumor recurrence was found during the 5 years of follow-up visits.Lessons:The possibility of multiple primary tumors of different histological origin should be considered when multiple different pancreatic lesions are detected on images. Computed tomography (CT) and magnetic resonance imaging (MRI) play key roles in the management of multiple tumors in the pancreas.

show abstract

Multiple primary malignancies in patients with sporadic pancreatic endocrine tumors

Cited by 11 publications

References 17 publications

Observational study of patients with gastroenteropancreatic and bronchial neuroendocrine tumors in Argentina: Results from the large database of a multidisciplinary group clinical multicenter study

Observational study of patients with gastroenteropancreatic and bronchial neuroendocrine tumors in Argentina: Results from the large database of a multidisciplinary group clinical multicenter study

Neuroendocrine Tumors of the Pancreas

Double primary tumors of the pancreas

Contact Info

Product

Resources

About